Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.

In this Phase II study, BAY 43–9006, taken orally for renal cell carcinoma, stabilized disease in 30% of patients, with 40% responding positively, although the targets remain unclear.

This Phase II study found that BAY 43-9006, given at 400 mg orally twice daily, led to stable disease in 30% and tumor reduction in 40% of renal cell carcinoma patients.

This study suggests that melanoma tumor cells exhibit intrinsic plasticity, challenging the applicability of the cancer stem cell model to this malignancy.

This study highlights that biological therapy, which stimulates the immune system through various methods like cytokine injections and immune checkpoint inhibition, shows promise for treating melanoma based on laboratory and clinical studies.

This letter to the editor shares a case study of lentiginous melanoma that appears clinically malignant but histopathologically benign, involving the BRAFV600R mutation.

This review discusses skin-related adverse effects from targeted cancer therapies in dermatology but does not provide new clinical results, emphasizing the essential role of dermatologists in managing these toxicities.

In this study, knockout of B-raf and C-raf genes in mice showed they are not needed for early melanocyte development, but are crucial for maintaining melanocyte stem cells, as evidenced by hair graying due to stem cell depletion.

This review discusses the adverse skin effects of EGFR inhibitors used in cancer treatment, exploring their mechanisms and offering strategies for prevention and management, but reports no new experimental findings.

The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.

This chapter reviews the skin side effects associated with targeted cancer therapies and emphasizes the importance of collaboration between oncologists and dermatologists without reporting new results.

In this study, five out of six patients treated with vemurafenib for metastatic melanoma experienced hair loss, which improved after topical steroid treatment.

This case report describes a 33-year-old woman with long-standing scalp issues and hair loss, revealing an unusual connection to past melanoma, but it presents no new research results.

This review discusses the epidemiology, risk factors, clinical features, and management of scalp melanomas, highlighting their high mortality rates and specific challenges in diagnosis and treatment; it reports no new research findings.

This review discusses the role of the TCL1 transgenic mouse model in understanding chronic lymphocytic leukemia biology and highlights the importance of exploring new pathogenetic and therapeutic targets.

This study found that all-trans and 9-cis retinoic acids increase steroid sulfatase activity in HL60 cells through mechanisms involving RARα/RXR heterodimers and multiple signaling pathways.

This study found that adjuvant sorafenib after hepatic resection improved overall survival in patients with intermediate and advanced hepatocellular carcinoma, compared to surgery only.

This study suggests that geranyl acetate may offer protective, anti-inflammatory, and cytoprotective effects against PPD-induced toxicity in keratinocyte cells, indicating its potential as a plant-derived treatment.

This review reports that natural compounds show promise in slowing skin photoaging by targeting cellular pathways in keratinocytes and fibroblasts. However, comprehensive clinical studies are needed to verify their efficacy and safety.

This study found that wedelolactone from Eclipta prostrata L. significantly reduced lung inflammation and fibrosis in mice with bleomycin-induced pulmonary fibrosis, suggesting potential therapeutic benefits through AMPK activation.

This review discusses the role of the hedgehog signaling pathway in hematological cancers and its potential as a therapeutic target; it reports no new clinical findings.

This review synthesizes current evidence on the Warburg effect in anaplastic thyroid carcinoma and discusses potential therapeutic targets, but reports no new clinical results.

This narrative review highlights the potential of naturally occurring compounds to target specific molecular pathways and overcome resistance in advanced and recurrent papillary thyroid cancer, offering new therapeutic possibilities beyond traditional treatments like surgery and lifelong hormone replacement.

This review highlights the limited effectiveness of current unlicensed treatments for male subfertility, like hormonal therapy and antioxidants, and emphasizes new drug discovery methods such as high-throughput screening and drug repurposing to improve treatment development for male subfertility.

This article reviews the potential of combining antiandrogenic and antiestrogenic treatments for BPH, highlighting aromatase inhibitors, but presents no new clinical results; further research is needed.

This study describes a newly recognized skin reaction associated with dasatinib, nilotinib, and ponatinib, marked by a lichenoid exanthem with severe pruritus that may necessitate discontinuation of therapy.

This study reports that a novel series of compounds can potently and selectively inhibit glycogen synthase kinase-3, which activates glycogen synthase in insulin receptor-expressing cells and primary rat hepatocytes.

This review discusses skin-related toxicities associated with targeted cancer therapies and emphasizes the need for dermatologists to understand and manage these adverse effects, but reports no new experimental results.

This review explores regenerative medicine approaches for vitiligo and alopecia areata, focusing on pathways for repopulating melanocytes and regrowing hair follicles, and summarizes potential treatments without reporting new clinical results.

This review discusses the JAK-STAT pathway and the use of FDA-approved JAK inhibitors for autoimmune and inflammatory diseases but reports no new research findings.